Read more here
Welcome to OncoGeneX
News & Events
Thursday, May 2 2013
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Wednesday, May 1 2013
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in...
Tuesday, Apr 30 2013
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment
OncoGenex is a biopharmaceutical company uniquely focused on cancer treatment resistance. We are committed to the development and commercialization of first-in-class, innovative therapies that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
Product Pipeline
Phase Three
Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
Information:
For PatientsFor PhysiciansFor InvestorsPhase Two
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
